Eli Lilly and Company (LLY)
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
Top executives from drugmakers big and small told CNBC that the next phase of the obesity drug market will be defined by a broader range of treatment options and improved access for patients. CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference in San Francisco.
FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate
Eli Lilly wins FDA Breakthrough Therapy status for sofetabart mipitecan in certain patients with platinum-resistant ovarian cancer.
Eli Lilly: Breakout To New Highs Sends A Clear Warning Shot
Eli Lilly remains the dominant force in obesity drugs, with strong momentum ahead of its anticipated Q2 oral obesity drug launch. Eli Lilly's oral drug entry is expected to lower barriers for new patients and accelerate global market penetration, especially outside the U.S. Intensifying generics competition and price wars, particularly in China and other ex-U.S. markets, present key risks, but Eli Lilly's diversified pipeline underpins confidence.
Eli Lilly, Nvidia team up in a $1B AI innovation lab.
About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life. - Get the latest news and data at finance.yahoo.com - Download the Yahoo Finance app on Apple (Click Here or Android (Click Here - Follow Yahoo Finance on social: X: Click Here Instagram: Click Here TikTok: Click Here Facebook: Click Here LinkedIn: Click Here
LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling
Eli Lilly stock declines after the FDA reportedly delays a decision on its obesity pill orforglipron, pushing the timeline to April and giving NVO more time.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Buy The Dip In LLY Stock?
Eli Lilly's recent decline of 3.76% following the FDA's delay regarding its oral weight-loss pill Orforglipron signifies a strategic buying chance rather than a matter of concern. Although the stock is trading at a premium valuation, the company's outstanding operational performance, strong financial condition, and encouraging long-term predictions in the obesity treatment field validate the decision to maintain or increase positions for long-term investors.
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?
Eli Lilly's Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Eli Lilly and Company (LLY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Eli Lilly and Company (LLY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
In the last few months of 2025, shares of pharmaceutical giant Eli Lilly and Company NYSE: LLY went on an undeniable hot streak. From the beginning of August 2025 to the end of the year, the stock rose 41%.
Eli Lilly (LLY) Laps the Stock Market: Here's Why
Eli Lilly (LLY) concluded the recent trading session at $1, signifying a +1.64% move from its prior day's close.
